NCT01012349Unknown2 期
Efficacy and Safety Clinical Trial of the Combination of Acetylsalicylic Acid, Sodium Bicarbonate and Citric Acid, Produced by Geolab Pharmaceutical Industries Ltd., Compared to Acetylsalicylic Acid (Aspirin ® - Bayer) in Patients With Episodic Tension-type Headache.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 152
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint is the rate of sustained response (percentage of subjects who have no pain) two hours after the drug administration.
研究概览
简要总结
This study aims is to evaluate, two hours after a single administration, the rate of sustained response produced by the association Geolab consisting of acetylsalicylic acid, sodium bicarbonate and anhydrous citric acid - oral powder, with the active comparator acetylsalicylic acid (Aspirin ® -- Bayer) - a simple tablet for the treatment of acute pain in patients with mild to moderate CTTE, using for both the visual analog scale pain - VAS.
详细描述
The secondary objectives of the study are to evaluate:
- Modification of gastric pH after administration of drugs by measuring with gastroesophageal pH Monitor, comparing the results between the groups;
- The incidence of administration of rescue medications, through the accounts of patients and researchers, comparing the results between the groups;
- The percentage of improvement in time 30, 60, 90 and 120 minutes after administration, using the visual analog scale (VAS), comparing the results between the groups;
- Evaluate the gastric symptoms before and after treatment by clinical investigation of patients, comparing the results between the groups;
- Evaluate the change in associated symptoms (photophobia, phonophobia, nausea, vomiting), using 4-point scale (0 - absent 1 - mild 2 - moderate 3 - severe), comparing the results between the groups;
- Assess the quantitative and qualitative parameters related to adverse reactions, comparing the results between the groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Agreed to participate in the study expressed by signing the two copies of the informed consent and informed consent (IC) after approved by the IRB;
- •Minimum age of 18 years;
- •Clinical history of TTH, according to the criteria of the International Classification of Headache of the International Headache Society, in face of crisis.
排除标准
- •Headache, migraine
- •Chronic Tension-Type Headache (CTTH)
- •Altered mental status
- •Vital signs changed
- •established or suspected pregnancy and lactation
- •History of allergy to components of study drugs
- •Current treatment with methotrexate
- •Current treatment with Antinauseants
- •Current treatment with anticoagulants such as heparin or coumarin-derivative
- •gastric or duodenal disorders, chronic or recurrent active
- •Liver and kidney disease severe
- •Use of medications that have drug interactions with AAS
研究组 & 干预措施
Comparator
Active Comparator
Acetylsalicylic acid - (Aspirin - Bayer)
干预措施: Aspirin - Bayer (Drug)
结局指标
主要结局
The primary efficacy endpoint is the rate of sustained response (percentage of subjects who have no pain) two hours after the drug administration.
时间窗: 0, 30, 60, 90 and 120 minutes
次要结局
- • Reduction of associated symptoms (photophobia, phonophobia, nausea, vomiting); • Symptoms stomach before and after treatment • Change in gastric pH after administration; • Incidence of administration of rescue medications; • Change in pain(30, 60, 90 and 120 minutes after administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"Essential HypertensionType 2 Diabetes MellitusNCT06226727Boryung Pharmaceutical Co., Ltd52
已完成
1 期
A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy ParticipantsHealthyNCT03723746Janssen Research & Development, LLC74
已完成
2 期
Safety Evaluation of 3K3A-APC in Ischemic StrokeIschemic StrokeNCT02222714ZZ Biotech, LLC110
已完成
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy AdultsRespiratory Syncytial Virus InfectionsNCT02114268MedImmune LLC342
Unknown
1 期
The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375Type 2 Diabetes MellitusNCT03848637Chong Kun Dang Pharmaceutical28